These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 17109182)

  • 41. Prevention, control and treatment of HIV-AIDS among injecting drug use in Bandung, Indonesia.
    Alisjahbana B; Susanto H; Roesli R; Yusuf H; Hinduan Z; Mase JC; Surahman E; van der Ven A
    Acta Med Indones; 2009 Jul; 41 Suppl 1():65-9. PubMed ID: 19920301
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Convergence of HIV seroprevalence among injecting and non-injecting drug users in New York City.
    Des Jarlais DC; Arasteh K; Perlis T; Hagan H; Abdul-Quader A; Heckathorn DD; McKnight C; Bramson H; Nemeth C; Torian LV; Friedman SR
    AIDS; 2007 Jan; 21(2):231-5. PubMed ID: 17197815
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Continued high prevalence of HIV, HBV and HCV among injecting and noninjecting drug users in Italy.
    Camoni L; Regine V; Salfa MC; Nicoletti G; Canuzzi P; Magliocchetti N; Rezza G; Suligoi B;
    Ann Ist Super Sanita; 2010; 46(1):59-65. PubMed ID: 20348620
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase 1 clinical trials of the National Institutes of Health Vaccine Research Center HIV/AIDS candidate vaccines.
    Robinson HL; Weinhold KJ
    J Infect Dis; 2006 Dec; 194(12):1625-7. PubMed ID: 17109331
    [No Abstract]   [Full Text] [Related]  

  • 45. Substance abuse vaccines.
    Orson FM; Kinsey BM; Singh RA; Wu Y; Gardner T; Kosten TR
    Ann N Y Acad Sci; 2008 Oct; 1141():257-69. PubMed ID: 18991962
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Changes in willingness to participate in HIV vaccine trials among HIV-negative injection drug users.
    Golub ET; Purvis LA; Sapun M; Safaeian M; Beyrer C; Vlahov D; Strathdee SA
    AIDS Behav; 2005 Sep; 9(3):301-9. PubMed ID: 16088366
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Chief health risks associated with intravenous heroin and cocaine abuse].
    Ben Diane MK; Feroni I; Poncet M; Obadia Y
    Presse Med; 2000 Mar; 29(8):453-7. PubMed ID: 10738515
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vaccines against drugs of abuse: a viable treatment option?
    Kantak KM
    Drugs; 2003; 63(4):341-52. PubMed ID: 12558457
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HIV infection and drugs of abuse: role of acute phase proteins.
    Samikkannu T; Rao KV; Arias AY; Kalaichezian A; Sagar V; Yoo C; Nair MP
    J Neuroinflammation; 2013 Sep; 10():113. PubMed ID: 24044608
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of benzylglycinamide by a HIV-seropositive polysubstance user: The changing pattern of novel psychoactive substance use among youths.
    Caloro M; Calabrò G; Kotzalidis GD; Cuomo I; Corkery JM; Vento AE; Lionetto L; De Filippis S; Ranieri V; Lonati D; Locatelli CA; de Pisa E; Di Tommaso A; Girardi P; Schifano F
    Addict Behav; 2016 Sep; 60():53-7. PubMed ID: 27088514
    [TBL] [Abstract][Full Text] [Related]  

  • 51. AIDS vaccine trial launched.
    Indian J Med Sci; 2000 Apr; 54(4):157-8. PubMed ID: 11227127
    [No Abstract]   [Full Text] [Related]  

  • 52. Drugs of abuse, immune modulation, and AIDS.
    Cabral GA
    J Neuroimmune Pharmacol; 2006 Sep; 1(3):280-95. PubMed ID: 18040805
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anti-drug vaccines to treat substance abuse.
    Kinsey BM; Jackson DC; Orson FM
    Immunol Cell Biol; 2009; 87(4):309-14. PubMed ID: 19333250
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drugs of Abuse Induced-Subversion of the Peripheral Immune Response and Central Glial Activity: Focus on Novel Therapeutic Approaches.
    Magrone T; Jirillo E
    Endocr Metab Immune Disord Drug Targets; 2019; 19(3):281-291. PubMed ID: 30488804
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recreational use of phenytoin, marijuana, and alcohol: a case report.
    Jessen K
    Neurology; 2004 Jun; 62(12):2330. PubMed ID: 15210913
    [No Abstract]   [Full Text] [Related]  

  • 56. Vaccines as a preventive tool for substance use disorder: A systematic review including a meta-analysis on nicotine vaccines' immunogenicity.
    Scendoni R; Bury E; Ribeiro ILA; Cameriere R; Cingolani M
    Hum Vaccin Immunother; 2022 Nov; 18(6):2140552. PubMed ID: 36351881
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cofactors that may influence vaccine responses.
    de Bruyn G
    Curr Opin HIV AIDS; 2010 Sep; 5(5):404-8. PubMed ID: 20978381
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Central Nervous System Vasculitis Due to Substance Abuse.
    Younger DS
    Neurol Clin; 2019 May; 37(2):425-440. PubMed ID: 30952417
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of periodic intake of drugs of abuse (morphine) on HIV dynamics: Mathematical model and analysis.
    Mutua JM; Wang FB; Vaidya NK
    Math Biosci; 2020 Aug; 326():108395. PubMed ID: 32485213
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The future of vaccines in the management of addictive disorders.
    Orson FM; Kinsey BM; Singh RA; Wu Y; Gardner T; Kosten TR
    Curr Psychiatry Rep; 2007 Oct; 9(5):381-7. PubMed ID: 17915077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.